Previous Page  8 / 19 Next Page
Show Menu
Previous Page 8 / 19 Next Page
Page Background

Page 38




June 19-20, 2017 Philadelphia, USA



International Conference on

Clinical and Experimental Dermatology

Volume 8, Issue 4 (Suppl)

J Clin Exp Dermatol Res, an open access journal


Dermatology 2017

June 19-20, 2017

Dermatological manifestations in pediatric rheumatology patients - The era of new biological


Sukesh Sukumaran



Suprakasan Sukumaran



University of Arkansas for Medical Sciences, USA


KIMS Medical Center, Qatar


heumatic diseases have a wide variety of cutaneous manifestations especially in the pediatric population. The dermatologic

manifestations may be the sole features in some of the rheumatic diseases especially at the initial presentation. The

common rheumatic diseases include the pediatric systemic lupus erythematosus, juvenile dermatomyositis, systemic onset

juvenile idiopathic arthritis, juvenile scleroderma and juvenile psoriasis. Dermatological manifestations are also seen with

less common rheumatic diseases including the periodic fever syndrome, SAPHO syndromes, Neutrophilic dermatoses and

pediatric vasculitis. The timely recognition of these rashes helps to diagnose the underlying rheumatic disease and also to start

appropriate immune modulation. With the new biological management of the rheumatic disease the challenges are higher as

initiation of the appropriate treatment within the therapeutic window will help to alleviate the long term damage to the joints

or internal organs. The biologics commonly used in pediatric rheumatology includes different anti TNF agents (etanercept,

adalimumab, infliximab), anti IL1 (anakinra, canakinumab, rilanocept), anti IL6- tocilizumab, anti B cell treatment with

rituximab and belimumab, co stimulatory inhibitors like abatacept, anti IL12/23 agent and IL17 agent like secukinumab. The

medications used to treat different rheumatic conditions lead to dermatological manifestations and implicated in the new

onset of cutaneous lupus and drug induced lupus. The topic is very important as the field of rheumatology and dermatology is

changing its face every day with the advent of new biologic medications. In this talk we are focusing on the rheumatic diseases

with cutaneous manifestations and new biologic medications.


Sukesh Sukumaran completed his Pediatric Residency from UMDNJ, Camden, NJ and Pediatric Rheumatology Fellowship from USC in Los Angeles, CA. He

attended his Medical School 21 years ago in University of Kerala, Trivandrum, India. He is currently an Assistant Professor of Pediatric Rheumatology at UAMS/

ACH. He was the Program Director for the Pediatric Rheumatology Fellowship Program at University of Florida prior to the current position. He is currently working

as the Chief Consultant at KIMS Hospital and Medical Center at Doha, Qatar. He is currently a Visiting Professor of Dermatology and Head of the Division of

Dermatology and Venereology at Palana Institute of Medical Sciences. He was the Head of the Division of Dermatology and Venereology at Trivandrum Medical

College and In-charge of the education for post-graduate & medical students and residents.

[email protected]

Sukesh Sukumaran et al., J Clin Exp Dermatol Res 2017, 8:4 (Suppl)

DOI: 10.4172/2155-9554-C1-059